Sugi Predict

Sugi Predict / Compounds / SCHEMBL1995195

SCHEMBL1995195

SCHEMBL1995195

CCOC(=O)COS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ STAT3 P40763 2/20 0.52
▸ ALDH1A1 P00352 5/20 0.51
▸ LMNA P02545 4/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ RECQL P46063 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ KMT2A Q03164 4/20 0.48
▸ POLB P06746 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ CTDSP1 Q9GZU7 1/20 0.46
▸ SIRT5 Q9NXA8 1/20 0.46
▸ CA2 P00918 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ NLRP3 Q96P20 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1872361 0.87 STAT3 (0.53) GAANPSR1STAT3ALDH1A1LMNA
SCHEMBL10488009 0.87 GAA (0.50) GAANPSR1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL1133915 0.86 STAT3 (0.47) GAANPSR1STAT3ALDH1A1LMNA
SCHEMBL2709615 0.86 GAA (0.48) GAANPSR1STAT3ALDH1A1LMNA
SCHEMBL23636404 0.85 GAA (0.47) GAANPSR1STAT3ALDH1A1LMNA
SCHEMBL21479430 0.85 GAA (0.47) GAANPSR1STAT3ALDH1A1LMNA
SCHEMBL17940959 0.85 GAA (0.47) GAANPSR1STAT3ALDH1A1LMNA
SCHEMBL23636475 0.85 GAA (0.47) GAANPSR1STAT3ALDH1A1LMNA
SCHEMBL6233467 0.85 GAA (0.47) GAANPSR1STAT3ALDH1A1LMNA
SCHEMBL17940927 0.85 GAA (0.47) GAANPSR1STAT3ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113087622-A Preparation method of eptazocine intermediate 广州一品红制药有限公司 2021-07-09 — — CN claimed
CN-112055712-A Processes and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections 吉利德科学公司 2020-12-08 — — CN claimed
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2025-03-27 — — US disclosed
US-12122765-B2 Methods and intermediates for preparing therapeutic compounds GILEAD SCIENCES, INC. (US) 2024-10-22 — — US disclosed
US-20240101533-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2024-03-28 — — US disclosed
CN-116854630-A Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections 吉利德科学公司 2023-10-10 — — CN disclosed
EP-4253366-A2 METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION Gilead Sciences, Inc. (US) 2023-10-04 — — EP disclosed
CN-116438177-A Targeted chimeric compounds, pharmaceutical compositions containing same, and preparation methods and uses thereof 江苏亚虹医药科技股份有限公司 2023-07-14 — — CN disclosed
CN-112055712-B Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections 吉利德科学公司 2023-07-14 — — CN disclosed
EP-3752496-B1 METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION GILEAD SCIENCES INC (US) 2023-07-05 — — EP disclosed
CN-113087622-B Preparation method of eptazocine intermediate 广州一品红制药有限公司 2023-03-31 — — CN disclosed
US-4500472-A CYCLIZATION, DEHYDRATION OF 1-(2-IMIDAZO-2-YLTHIO) PHENYLIMINO THIOCARBONYL) PIPERAZINE) CIBA-GEIGY CORPORATION (US) 1985-02-19 — — US disclosed
US-4477379-A NEUROLEPTIC AGENTS CIBA-GEIGY CORPORATION (US) 1984-10-16 — — US disclosed
US-4460587-A ANTIPSYCHOTIC AGENTS, ANTIALLERGENS CIBA-GEIGY CORPORATION (US) 1984-07-17 — — US disclosed
US-4460508-A 5-Diazacycloalkylimidazo[1,2-c][1,3]benzodiazepines CIBA-GEIGY CORPORATION (US) 1984-07-17 — — US disclosed
US-4459232-A NEUROLEPTIC, ANTIHISTAMINES CIBA-GEIGY CORPORATION (US) 1984-07-10 — — US disclosed
US-4444688-A NEUROLEPTICS CIBA-GEIGY CORPORATION (US) 1984-04-24 — — US disclosed
US-4391808-A NEUROLEPTIC AND ANTIPSYCHOTIC AGENTS CIBA-GEIGY CORPORATION (US) 1983-07-05 — — US disclosed
US-4362666-A ANTIDEPRESSANTS CIBA-GEIGY CORPORATION (US) 1982-12-07 — — US disclosed
US-4316900-A Piperazinopyrrolobenzodiazepines CIBA-GEIGY CORPORATION (US) 1982-02-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12122765-B2 Methods and intermediates for preparing therapeutic compounds CYP11A1, CYP11B1, CYP11B2 GAA 273/4885NPSR1 2495/4885STAT3 3289/4885
US-20240101533-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 GAA 273/4885NPSR1 2495/4885STAT3 3289/4885
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 GAA 273/4885NPSR1 2495/4885STAT3 3289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.